Journal Basic Info
- Impact Factor: 1.989**
- H-Index: 6
- ISSN: 2637-4625
- DOI: 10.25107/2637-4625
Major Scope
- Surgery & Surgical Research
- Gynecological Surgery
- Podiatric Surgery
- Endocrine Surgery
- Trauma Surgery
- Neurological Surgery
- Robotic Surgery
- General Surgery
Abstract
Citation: World J Surg Surg Res. 2022;5(1):1405.DOI: 10.25107/2637-4625.1405
Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Mesothelioma
Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi, Mizumoto, Takuji Fujita, Yang Liu, Satoshi Wakama, Syouzou Sako, Nobuyuki Takao, Toshiyuki Kitai, Kanji Katayama, Yasuyuki Kamada, Keizou Taniguchi and Daisuke Fujimoto
Asian School of Peritoneal Surface Malignancy Treatment, Japan Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kishiwada Tokushukai Hospital, Japan Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kusatsu General Hospital, Japan Department of Surgery, Mizonokuchi Hospital, Teikyo University, School of Medicine, Japan
*Correspondance to: Yutaka Yonemura
PDF Full Text Research Article | Open Access
Abstract:
Purpose: The purpose of the manuscript is to verify the effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (NLHIPEC) and Neoadjuvant Intraperitoneal/ Systemic Chemotherapy (NIPS) on PCI and postoperative survivals of patients with Peritoneal Mesothelioma (PM). Patients and Methods: From 2007 to 2021, 92 PM patients were treated. The population was divided into three groups: No Neoadjuvant Chemotherapy (no NAC), Neoadjuvant Systemic Chemotherapy (NASC) and Neoadjuvant Intraperitoneal/Systemic Chemotherapy (NIPS) and Neoadjuvant Laparoscopic HIPEC (NLHIPEC). Results: Among 92 patients, NASC, and NLHIPEC plus or minus (±) NIPS and no NAC were performed in 34, 33, and 25 patients, respectively. Ten patients underwent one cycle of NLHIPC. PCIs in 2nd laparoscopy one month after NLHIPC alone were 14.1 ± 11.1, and those in the 1st laparoscopy were 19.3 ± 9.4. PCIs of 17 patients received both NLHIPEC plus NIPS reduced from 25.0 ± 10.7 to17.3 ± 7.6 (P=0.039). Operations were performed in 67 (72.8%), and were done in 12 (48%), 27 (82.5%), and 28 (82.1%) of no NAC, NLHIPEC ± NIPS and NASC group, respectively. Rates of CCR-0 in each group were 19.3%, 37.5%, and 20.6%, respectively. CCR-0 rate of NLHIPEC ± NIPS group was significantly higher than that of no NAC group (P=0.0065, X2=7.85). Post-treatment survival of patients treated with NLHIPEC ± NIPS was superior to those of other treatment groups (P=0.016, X2=5.799). Median survival time of NLHIPEC ± NIPS, NASC, and non NAC groups were 47.4, 15.5 and 6.0 months, respectively. Conclusion: This retrospective study suggests that NLHIPEC ± NIPS may increase CCR-0 resection rate by reducing PCI scores and may improve post operative survival.
Keywords:
Peritoneal mesothelioma; Mesothelioma; Intraperitoneal chemotherapy; HIPEC; Peritonectomy
Cite the Article:
Yonemura Y, Ishibashi H, Akiyoshi, Mizumoto, Fujita T, Liu Y, et al. Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Mesothelioma. World J Surg Surgical Res. 2022; 5: 1405..